Navigation Links
GeoVax Presents Data at AIDS Vaccine 2008 Conference
Date:10/16/2008

ATLANTA, Oct. 16 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, presented data on their AIDS vaccine (trial HVTN 065) at the AIDS Vaccine 2008 conference, on October 15 in Cape Town, South Africa. This conference comes at an exciting time for GeoVax, which is preparing to enter Phase 2 trials for its vaccine.

The presentation, titled "Two HIV DNA Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN 065)," was given by Dr. Paul A. Goepfert, M.D., Associate Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The trial results reveal the GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune responses) at both low (1/10th) dose and full doses. Other highlights included:

-- GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the majority of trial participants.

-- 80 percent of both the low and full dose trial participants responded to the vaccine which stimulated anti-HIV T-cell (white blood cell) and antibody responses.

-- More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas response rates for T cells were similar for the 1/10th and full dose.

-- Two DNA primes were more effective than one DNA prime or no DNA primes at eliciting T cell responses.

-- The 2nd MVA vaccination positively increased CD8 T cell and antibody responses.

"As the entire world tries to find a solution for the HIV/AIDS crisis, GeoVax, a front runner in the search for an effective vaccine, is on the verge of entering Phase 2 trials," said Bob McNally, CEO and President of GeoVax Labs, Inc. "The AIDS Vaccine 2008 conference is a
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... HOUSTON, TX and VANCOUVER ... or the "Company") (TSX-V: EPI) announced today that it ... in the US an Investigation New Drug ("IND") application ... in prostate cancer patients.  Approval of the IND application ... testing of EPI-506 in the US.  ...
(Date:3/31/2015)... 31, 2015  Sonoa Health, a health tech startup ... developed a world-first consumer health portal, Health&, which brings ... devices and more. Today, the Company appointed ... CEO, who brings to the table more than 18-years ... included working closely with the biggest names in Silicon ...
(Date:3/31/2015)... NEW YORK , March 31, 2015 /PRNewswire/ ... biopharmaceutical company advancing protein biologic therapies and oncology ... marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: ... the country,s Ministry of Food and Drug Safety ... (KTR) for MuGard, its oncology supportive-care treatment for ...
(Date:3/31/2015)... 31, 2015 Diasome Pharmaceuticals, Inc. ( ... Inc., that a United States patent has recently been ... , Entitled “Lipid Construct for Delivery of ... matter claims related to the use of Diasome’s proprietary ... injected insulin to more effectively reach the liver’s metabolic ...
Breaking Biology Technology:ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2
... Earlier Identification of Toxicity, Efficacy for Pharmaceutical ... ... CITY, Calif., Aug. 29 Codexis, Inc., a private,biotechnology company ... licensed important intellectual property,from the California Institute of Technology for ...
... Corporation,(Nasdaq: DRRX ) announced today that James ... the NewsMakers in the Biotech Industry Investment,Conference to ... 6, 2007 at 11:30 a.m.,Eastern Time. (Logo: ... of the presentation will be available by accessing,DURECT,s ...
... Pharmion Corporation,(Nasdaq: PHRM ) today announced that ... Fast Track designation for oral Azacitidine in the,treatment ... are designed to facilitate the development and,expedite the ... treat serious or,life-threatening conditions and that demonstrate the ...
Cached Biology Technology:Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
(Date:3/18/2015)... Florida , March 18, 2015 ... as businesses, new revolutionary smart wallets and apps continue to ... Companies currently entrenched in the mobile payment industry in focus ... Group Holding Ltd. (NYSE: BABA ), Apple Inc. ... GOOG ) and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... known as Ecstasy, can reverse the symptoms of Parkinson's ... condition, according to new research at Duke University Medical ... animals do not suggest Parkinson's disease patients should find ... with many dangerous side effects. The findings rather indicate ...
... how the immune system reacts to strains of ... healthy people, or so-called "community-acquired" infections--has shown for ... deadly and better at evading human immune defenses ... in hospitals and other health-care settings. , In ...
... further evidence that one of the oldest biological laws ... sump tank reservoirs of machines in an engineering workshop ... Microbiology. , Scientists from the Centre for Ecology & ... abundance and genetic diversity of bacteria living in oil-based ...
Cached Biology News:Amphetamines reverse Parkinson's disease symptoms in mice 2Amphetamines reverse Parkinson's disease symptoms in mice 3Amphetamines reverse Parkinson's disease symptoms in mice 4Emerging staph strains found to be increasingly deadly and deceptive 2Emerging staph strains found to be increasingly deadly and deceptive 3Applying ecological laws to bacteria 2
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Recombinant Human PTP1B (aa 2-321), CF...
Biology Products: